Characterization of responder groups to secukinumab treatment in moderate to severe plaque psoriasis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Characterization of responder groups to secukinumab treatment in moderate to severe plaque psoriasis

Published:2019-07-16 Issue:8 Volume:31 Page:769-775
ISSN:0954-6634
Container-title:Journal of Dermatological Treatment
language:en
Short-container-title:Journal of Dermatological Treatment

Author:

Pinter Andreas¹,Gerdes Sascha²,Papavassilis Charis³,Reinhardt Maximilian⁴

Affiliation:

1. Department of Dermatology, Venereology and Allergology, University Hospital Frankfurt, Frankfurt am Main, Germany;

2. Psoriasis-Center, Department of Dermatology, University Medical Center Schleswig-Holstein, Kiel, Germany;

3. Novartis Pharma AG, Basel, Switzerland;

4. Novartis Pharma GmbH, Nürnberg, Germany

Funder

Novartis Pharma GmbH

Publisher

Informa UK Limited

Subject

Dermatology

Link

https://www.tandfonline.com/doi/pdf/10.1080/09546634.2019.1626973

Reference41 articles.

1. PASI90 response: the new standard in therapeutic efficacy for psoriasis

2. Considerations for Systemic Treatment of Psoriasis in Obese Patients

3. Obesity in autoimmune diseases: Not a passive bystander

4. Elevated odds of metabolic syndrome in psoriasis: a population‐based study of age and sex differences

5. Risk of Myocardial Infarction in Patients With Psoriasis

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Residual metabolic burden in young psoriasis patients successfully treated with biologics;2024-09-02

2. Metabolic Syndrome and Psoriasis: Pivotal Roles of Chronic Inflammation and Gut Microbiota;International Journal of Molecular Sciences;2024-07-25

3. Psoriatic arthritis, biologic therapy experience, body mass index, and onset age of psoriasis were independent factors of secukinumab discontinuation in patients with psoriasis;Expert Review of Clinical Pharmacology;2024-07-12

4. Psoriasis Comorbidities and Their Treatment Impact;Dermatologic Clinics;2024-07

5. Efficacy and safety of secukinumab in psoriasis: five-year real life experience;Anais Brasileiros de Dermatologia;2024-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3